Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2026)
20 slides from Terumo's investor presentation, May 15, 2026
Slide 1: GS26 Final Year and Beyond & Terumo Neuro Growth Roadmap
GS26 Final Year and Beyond ＆ Terumo Neuro Growth Roadmap Hikaru Samejima Chief Executive Officer Terumo Corporation Carsten Schroeder President Terumo Neuro May 15, 2026
Slide 2: Forward-Looking Statements and Use of Document
Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performanc
Slide 3: Achieve All GS26 Financial Targets
Achieve All GS26 Financial Targets Revenue Growth Operating Profit ROIC Target: High single-digit Target: 20%+ Target: 10％+ 5-Year CAGR FY26 FY26 12%（7%） 20% 10% Revenue CAGR in parentheses is calculated based on the assumed exchange rate at the time of GS26's announcement. ※Excluding new M&A execut
Slide 4: Key Growth Drivers for FY26
Key Growth Drivers for FY26 C&V TMCS Strong fundamentals in the endovascular Global CDMO business (including new business product launches) Pricing measures, primarily in North America Continued pricing measures Ultimaster Nagomi WEB PLAJEX TBCT Terumo Organ Technologies Revenue growth by
Slide 5: Terumo Neuro (TN) Growth Roadmap
Terumo Neuro (TN) Growth Roadmap ©TERUMO CORPORATION 5
Slide 6: Executive Summary
Executive Summary Business Overview and History Offer Hemorrhagic stroke and Ischemic stroke treatment solutions Grown to be complete and class leading, since the acquisitions of MicroVention and Sequent Medical Performance Trends Consistently delivered double digit revenue growth Driven by its lead
Slide 7: Overview of Neurovascular Business
Overview of Neurovascular Business A Hemorrhagic stroke happens An Ischemic stroke happens when a blood vessel in the brain forms a when a blood clot blocks blood flow to weak, bubble-like area that bursts and the brain, causing brain cells to be bleeds damaged or die Portfolio Therapeutics Intrasac
Slide 8: History of Neurovascular Business
History of Neurovascular Business The Neurovascular business has grown to be complete and class leading, since the acquisition of MicroVention and Sequent Medical MircroVention Terumo Corporation acquired Acquired Sequent Medical Rebranded to “Preserving and Restoring founded MircroVention Terumo Ne
Slide 9: TN Sales Trends and Breakdown
TN Sales Trends and Breakdown Business Growth FY25 Financials Consistent & Double Digit CAGR Therapeutics is ~70% of Annual Sales $M* 800 700 600 500 Sales (FY25) 400 $ 710M 300 200 100 - FY06 FY10 FY15 FY20 FY 25 *Based on reported FY FX rate ©TERUMO CORPORATION 9
Slide 10: TN Growth Strategy
TN Growth Strategy Continue to deliver above-market growth through three strategic pillars 1 Introduce new product offerings and Leverage Core Portfolio Expand clinical evidence Growth of existing core business 2 Operational Improvements EXPAND Expand production Production Capacity & IMPROVE capacit
Slide 11: Key Strength of TN: Integration and Iterations on Technology
1 Leverage Core Portfolio Key Strength of TN: Integration and Iterations on Technology Setting new standard of care through the integration and iterations on technology, earning strong No.1 in specific areas Coils WEBTM (Intrasaccular device for treatment of intracranial wide neck bifurcation aneury
Slide 12: Key Strength of TN: Clinical Evidence Generation
1 Leverage Core Portfolio Key Strength of TN: Clinical Evidence Generation TN is at the forefront of clinical studies in neurointerventional devices Over 2,000 patients are currently enrolled in post Leading innovation in neuro research approval studies globally for key products +4,900 Patients USA
Slide 13: Growth Opportunities in Intrasaccular (WEB)
1 Leverage Core Portfolio Growth Opportunities in Intrasaccular (WEBTM) The intrasaccular device market is expected to grow at over 10% WEBTM Embolization System is a first-in-class intrasaccular technology (for intracranial wide neck bifurcation aneurysms) refined over 15 years Product & Clinical R
Slide 14: Growth Opportunities in Ischemic (SOFIA)
1 Leverage Core Portfolio Growth Opportunities in Ischemic (SOFIATM) Aspiration Catheters are used in 90% of all Ischemic Stroke cases, with the latest introduction of SuperBore (large diameter) catheters Continue to invest in clinical evidence generation and future SOFIATM versions Aspiration Being
Slide 15: Operational Efficiency: Margin & Capacity Improvements
2 Operational Improvements Operational Efficiency: Margin & Capacity Improvements Gross margin improvements Costa Rica advantages Improvement in COGS (Cost of Goods Sold) while National strategy (tax benefits, free zone) maintaining high quality Presence of most US MedTech competition Collaboration
Slide 16: Further Growth Opportunities in Adjacent Markets
3 Adjacent Markets Further Growth Opportunities in Adjacent Markets Neurovascular market continues to grow at 6% annually with the expanding presence of smaller companies and treatment solutions for new disease areas (e.g., Chronic Subdural Hematoma) Develop offerings for those areas with deliberate
Slide 17: Future of TN
Future of TN Driving further the Neurovascular business and company-wide growth Develop class leading and commercially scalable solutions for core therapies Pipeline of new product offerings (2026-2031) Clinical evidence expansion Preserving and Operational Efficiency Restoring Intrasaccular New! Ne
Slide 18: Next Growth Stage
Next Growth Stage ©TERUMO CORPORATION 18
Slide 19: Toward GS31
Toward GS31 Global Top-tier FY26 GS31 Continue striving for even higher levels of growth and performance ©TERUMO CORPORATION 19
Slide 20: ~“TERUMO
~“TERUMO